BRPI0819783A2 - Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos. - Google Patents

Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos.

Info

Publication number: BRPI0819783A2
Authority: BR; Brazil
Prior art keywords: adenovirus sadv; subfamily; simian; simian subfamily; sadv
Prior art date: 2007-11-28

Application number

BRPI0819783-0A

Other languages

English (en)

Inventor

Soumitra Roy

James M Wilson

Luc H Vandenberghe

Original Assignee

Univ Pennsylvania

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-28

Filing date

2008-11-24

Publication date

2015-06-23

2008-11-24 Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania

2015-06-23 Publication of BRPI0819783A2 publication Critical patent/BRPI0819783A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

BRPI0819783-0A 2007-11-28 2008-11-24 Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos. BRPI0819783A2 (pt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US449907P	2007-11-28	2007-11-28
US446107P	2007-11-28	2007-11-28
US446407P	2007-11-28	2007-11-28
US453207P	2007-11-28	2007-11-28
US450707P	2007-11-28	2007-11-28
US454107P	2007-11-28	2007-11-28
PCT/US2008/013066 WO2009073104A2 (en)	2007-11-28	2008-11-24	Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38

Publications (1)

Publication Number	Publication Date
BRPI0819783A2 true BRPI0819783A2 (pt)	2015-06-23

Family

ID=40380705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0819783-0A BRPI0819783A2 (pt)	2007-11-28	2008-11-24	Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos.

Country Status (20)

Country	Link
US (3)	US8685387B2 (pt)
EP (2)	EP3128010A1 (pt)
JP (3)	JP5740158B2 (pt)
KR (3)	KR101662574B1 (pt)
CN (1)	CN101883858B (pt)
AU (1)	AU2008331906B2 (pt)
BR (1)	BRPI0819783A2 (pt)
CA (2)	CA2706258C (pt)
CY (1)	CY1118351T1 (pt)
DK (1)	DK2220241T3 (pt)
ES (1)	ES2607029T3 (pt)
HR (1)	HRP20161573T1 (pt)
HU (1)	HUE032142T2 (pt)
LT (1)	LT2220241T (pt)
MX (2)	MX2010005858A (pt)
PL (1)	PL2220241T3 (pt)
PT (1)	PT2220241T (pt)
SG (1)	SG10201604001XA (pt)
SI (1)	SI2220241T1 (pt)
WO (1)	WO2009073104A2 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2621165T3 (es)	2007-11-28	2017-07-03	The Trustees Of The University Of Pennsylvania	Adenovirus de simio de la subfamilia B SADV-28, -27, -29, -32, -33 y -35 y usos de los mismos
BRPI0819774A2 (pt)	2007-11-28	2014-10-14	Univ Pennsylvania	Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
ES2607029T3 (es)	2007-11-28	2017-03-28	The Trustees Of The University Of Pennsylvania	Adenovirus que comprende una proteína hexónica de la cápside del adenovirus E de simio SAdV-39 y usos de la misma
JP5661476B2 (ja)	2008-03-04	2015-01-28	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
WO2010051367A1 (en) *	2008-10-31	2010-05-06	The Trustees Of The University Of Pennsylvania	Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
WO2010085984A1 (en) *	2009-02-02	2010-08-05	Okairos Ag	Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
MX2011007980A (es)	2009-02-02	2011-08-17	Okairos Ag	Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
CA2762203A1 (en)	2009-05-29	2010-12-02	Soumitra Roy	Simian adenovirus 41 and uses thereof
CA2779632C (en)	2009-11-09	2019-08-20	Jason Gall	Simian adenovirus and methods of use
WO2011057254A2 (en) *	2009-11-09	2011-05-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Simian adenoviral vector-based vaccines
AU2011332025B2 (en) *	2010-11-23	2015-06-25	The Trustees Of The University Of Pennsylvania	Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
US9254320B2 (en)	2010-12-17	2016-02-09	Globeimmune, Inc.	Compositions and methods for the treatment or prevention of human adenovirus-36 infection
US10221218B2 (en)	2011-05-10	2019-03-05	The Regents Of The University Of California	Adenovirus isolated from titi monkeys
WO2012154994A2 (en) *	2011-05-10	2012-11-15	The Regents Of The University Of Californa	A novel adenovirus isolated from titi monkeys
GB201108879D0 (en) *	2011-05-25	2011-07-06	Isis Innovation	Vector
TWI623618B (zh)	2011-07-12	2018-05-11	傳斯堅公司	Ｈｂｖ聚合酶突變體
WO2013045658A1 (en)	2011-09-29	2013-04-04	Transgene Sa	Immunotherapy composition and regimen for treating hepatitis c virus infection
TW201321016A (zh)	2011-09-29	2013-06-01	Transgene Sa	免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
EP2850194A4 (en)	2012-05-18	2016-06-08	Univ Pennsylvania	APE-ADENOVIRES A1302, A1320, A1331 AND A1337 OF THE FAMILY E AND USES THEREOF
CN104619839A (zh) *	2012-08-03	2015-05-13	西塞医疗中心	药物递送蛋白质的增强运输的突变体的分离
EP2971008B1 (en)	2013-03-14	2018-07-25	Salk Institute for Biological Studies	Oncolytic adenovirus compositions
EP3151866B1 (en)	2014-06-09	2023-03-08	Voyager Therapeutics, Inc.	Chimeric capsids
CN108064275A (zh)	2014-09-24	2018-05-22	萨克生物研究学院	溶瘤肿瘤病毒及使用方法
MX389213B (es)	2014-10-06	2025-03-20	Univ Pennsylvania	Composiciones y métodos para el aislamiento de células tumorales circulantes (ctc).
MX2017005834A (es)	2014-11-05	2017-11-17	Voyager Therapeutics Inc	Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2017006216A (es)	2014-11-14	2018-08-29	Voyager Therapeutics Inc	Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
KR20230145206A (ko)	2014-11-14	2023-10-17	보이저 테라퓨틱스, 인크.	조절성 폴리뉴클레오티드
WO2016094783A1 (en)	2014-12-12	2016-06-16	Voyager Therapeutics, Inc.	Compositions and methods for the production of scaav
US20180028626A1 (en)	2015-02-13	2018-02-01	Transgene Sa	Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en)	2015-02-20	2016-08-25	Transgene Sa	Combination product with autophagy modulator
MX2017016105A (es) *	2015-06-12	2018-05-15	Glaxosmithkline Biologicals Sa	Polinucleotidos y polipeptidos de adenovirus.
EP3384035A4 (en) *	2015-12-02	2019-08-07	Voyager Therapeutics, Inc.	ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES
ES2933174T3 (es)	2016-02-23	2023-02-02	Salk Inst For Biological Studi	Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
WO2017147265A1 (en)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	High throughput assay for measuring adenovirus replication kinetics
EP3448874A4 (en)	2016-04-29	2020-04-22	Voyager Therapeutics, Inc.	COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en)	2016-04-29	2022-04-12	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
US20190134190A1 (en)	2016-05-04	2019-05-09	Transgene Sa	Combination therapy with cpg tlr9 ligand
KR102652994B1 (ko)	2016-05-18	2024-04-01	보이저 테라퓨틱스, 인크.	조절성 폴리뉴클레오티드
JP7220080B2 (ja)	2016-05-18	2023-02-09	ボイジャーセラピューティクスインコーポレイテッド	ハンチントン病治療組成物及び方法
AU2017313917B2 (en)	2016-08-18	2023-12-21	The Regents Of The University Of California	CRISPR-Cas genome engineering via a modular AAV delivery system
WO2018044933A1 (en)	2016-08-30	2018-03-08	The Regents Of The University Of California	Methods for biomedical targeting and delivery and devices and systems for practicing the same
WO2018069316A2 (en)	2016-10-10	2018-04-19	Transgene Sa	Immunotherapeutic product and mdsc modulator combination therapy
EP3532082A4 (en)	2016-12-12	2020-08-26	Salk Institute for Biological Studies	SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
SG11201909868YA (en)	2017-05-05	2019-11-28	Voyager Therapeutics Inc	Compositions and methods of treating huntington's disease
AU2018261790B2 (en)	2017-05-05	2024-10-03	Voyager Therapeutics, Inc.	Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JOP20190269A1 (ar)	2017-06-15	2019-11-20	Voyager Therapeutics Inc	بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en)	2017-07-17	2019-01-24	Voyager Therapeutics, Inc.	Trajectory array guide system
KR102850887B1 (ko)	2017-08-03	2025-08-28	보이저 테라퓨틱스, 인크.	Aav의 전달을 위한 조성물 및 방법
MX2020003042A (es)	2017-09-29	2020-11-18	Voyager Therapeutics Inc	Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
TW202413649A (zh)	2017-10-16	2024-04-01	美商航海家醫療公司	肌萎縮性脊髓側索硬化症(als)之治療
EP4454654A3 (en)	2017-10-16	2025-02-19	Voyager Therapeutics, Inc.	Treatment of amyotrophic lateral sclerosis (als)
SG11202003398SA (en)	2017-10-31	2020-05-28	Janssen Vaccines & Prevention Bv	Adenovirus vectors and uses thereof
KR20200074987A (ko) *	2017-10-31	2020-06-25	얀센 백신스 앤드 프리벤션 비.브이.	아데노바이러스 및 이의 용도
BR112020007698A2 (pt)	2017-10-31	2020-10-06	Janssen Vaccines & Prevention B.V.	Sequência de ácido nucleico isolada, vetor, seu método de produção, célularecombinante, composição imunogênica, método para induzir uma resposta imune em um indivíduo, vacina e seu método de produção
KR20200077559A (ko)	2017-10-31	2020-06-30	얀센 백신스 앤드 프리벤션 비.브이.	아데노바이러스 및 이의 용도
JP7430395B2 (ja)	2018-04-09	2024-02-13	ソークインスティテュートフォーバイオロジカルスタディーズ	複製特質が増強された腫瘍溶解性アデノウイルス組成物
EP3794126A1 (en)	2018-05-15	2021-03-24	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of parkinson's disease
EP3807404A1 (en)	2018-06-13	2021-04-21	Voyager Therapeutics, Inc.	Engineered 5' untranslated regions (5' utr) for aav production
SG11202100139VA (en)	2018-07-17	2021-02-25	Neuromyon Inc	Treatment of neuropathy with dna constructs expressing igf-1 isoforms
MX2021000810A (es)	2018-07-24	2021-04-28	Voyager Therapeutics Inc	Sistemas y metodos para producir formulaciones de terapia genetica.
EP3856762A1 (en)	2018-09-28	2021-08-04	Voyager Therapeutics, Inc.	Frataxin expression constructs having engineered promoters and methods of use thereof
TW202035689A (zh)	2018-10-04	2020-10-01	美商航海家醫療公司	測量病毒載體粒子的效價及強度之方法
SG11202103425YA (en)	2018-10-05	2021-05-28	Voyager Therapeutics Inc	Engineered nucleic acid constructs encoding aav production proteins
TW202028468A (zh)	2018-10-15	2020-08-01	美商航海家醫療公司	用於桿狀病毒/Sf9系統中rAAV之大規模生產的表現載體
AU2020216480A1 (en)	2019-01-31	2021-09-09	Oregon Health & Science University	Methods for using transcription-dependent directed evolution of AAV capsids
US20230256057A1 (en)	2020-07-13	2023-08-17	Transgene	Treatment of immune depression
EP4284335A1 (en)	2021-02-01	2023-12-06	RegenxBio Inc.	Gene therapy for neuronal ceroid lipofuscinoses
WO2022218997A1 (en)	2021-04-12	2022-10-20	Centre National De La Recherche Scientifique (Cnrs)	Novel universal vaccine presenting system
WO2023213764A1 (en)	2022-05-02	2023-11-09	Transgene	Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
US20250276095A1 (en)	2024-03-04	2025-09-04	Kate Therapeutics, Inc.	Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
WO2025226842A1 (en)	2024-04-24	2025-10-30	Kate Therapeutics, Inc.	Expression control by drg-expressed mirnas
WO2025226841A1 (en)	2024-04-24	2025-10-30	Kate Therapeutics, Inc.	Gene therapy approach for treating disorders associated with tnnt2
WO2026011008A1 (en)	2024-07-02	2026-01-08	Kate Therapeutics, Inc.	Expression control by skeletal muscle-expressed mirnas
WO2026011009A1 (en)	2024-07-02	2026-01-08	Kate Therapeutics, Inc.	Compositions and methods for muscle disorders

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1364343A1 (ru)	1984-07-13	1988-01-07	Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов	Способ получени человеческого лейкоцитарного интерферона альфа-2
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4732683A (en)	1986-12-02	1988-03-22	Biospectrum, Inc.	Purification method for alpha interferon
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5240846A (en)	1989-08-22	1993-08-31	The Regents Of The University Of Michigan	Gene therapy vector for cystic fibrosis
US6174666B1 (en)	1992-03-27	2001-01-16	The United States Of America As Represented By The Department Of Health And Human Services	Method of eliminating inhibitory/instability regions from mRNA
CA2200869A1 (en)	1994-10-19	1996-05-02	Bruce C. Trapnell	Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5856152A (en)	1994-10-28	1999-01-05	The Trustees Of The University Of Pennsylvania	Hybrid adenovirus-AAV vector and methods of use therefor
JP3565859B2 (ja)	1994-10-28	2004-09-15	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	改良されたアデノウイルスおよびその使用法
WO1998010087A1 (en)	1996-09-06	1998-03-12	Trustees Of The University Of Pennsylvania	Chimpanzee adenovirus vectors
CA2264482A1 (en)	1996-09-06	1998-03-12	The Trustees Of The University Of Pennsylvania	An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US5922315A (en)	1997-01-24	1999-07-13	Genetic Therapy, Inc.	Adenoviruses having altered hexon proteins
US5891994A (en)	1997-07-11	1999-04-06	Thymon L.L.C.	Methods and compositions for impairing multiplication of HIV-1
AU9319198A (en)	1997-09-19	1999-04-05	Trustees Of The University Of Pennsylvania, The	Methods and vector constructs useful for production of recombinant aav
EP1015619A1 (en)	1997-09-19	2000-07-05	The Trustees Of The University Of Pennsylvania	Methods and cell line useful for production of recombinant adeno-associated viruses
GB9720585D0 (en)	1997-09-26	1997-11-26	Smithkline Beecham Biolog	Vaccine
AU1822499A (en) *	1997-12-12	1999-06-28	Saint Louis University	Ctip, a novel protein that interacts with ctbp and uses therefor
ES2235470T3 (es)	1998-03-20	2005-07-01	The Trustees Of The University Of Pennsylvania	Composiciones y metodos para la produccion libre de cooperadores de virus adnoasociados recombinantes.
WO2000011140A1 (en)	1998-08-20	2000-03-02	The Wistar Institute Of Anatomy And Biology	Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
US6258595B1 (en)	1999-03-18	2001-07-10	The Trustees Of The University Of Pennsylvania	Compositions and methods for helper-free production of recombinant adeno-associated viruses
CN1326873C (zh)	2000-01-31	2007-07-18	史密丝克莱恩比彻姆生物有限公司	用于hiv预防或治疗性免疫的疫苗
US6740525B2 (en)	2000-02-09	2004-05-25	Genvec, Inc.	Adenoviral capsid containing chimeric protein IX
US20040136963A1 (en) *	2001-06-22	2004-07-15	The Trustees Of The University Of Pennsylvania	Simian adenovirus vectors and methods of use
ES2375557T3 (es) *	2001-06-22	2012-03-02	The Trustees Of The University Of Pennsylvania	Adenovirus recombinantes que comprenden prote�?nas de adenovirus de simios y usos de los mismos.
HU230488B1 (hu)	2001-11-21	2016-08-29	The Trustees Of The University Of Pennsylvania	Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
ES2478625T3 (es)	2003-06-20	2014-07-22	The Trustees Of The University Of Pennsylvania	Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos
US7291498B2 (en)	2003-06-20	2007-11-06	The Trustees Of The University Of Pennsylvania	Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
CA2880060C (en) *	2004-01-23	2018-03-13	Agostino Cirillo	Chimpanzee adenovirus vaccine carriers
EP1718315A4 (en)	2004-02-06	2008-08-13	Univ Monash	HIGH DOSE USE OF SULFATED POLYSACCHARIDES IN SHORT INTERVALS FOR THE TREATMENT OF INFECTIONS
BRPI0518146A (pt)	2004-10-14	2008-10-28	Crucell Holland Bv	kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
US7745147B2 (en)	2005-02-12	2010-06-29	Viranative Ab	Methods and uses of antibodies in the purification of interferon
KR101451620B1 (ko) *	2005-05-12	2014-10-21	글락소 그룹 리미티드	백신 조성물
JP5889514B2 (ja)	2006-04-28	2016-03-22	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	改変アデノウイルスヘキソンタンパク質およびその用途
BRPI0819774A2 (pt)	2007-11-28	2014-10-14	Univ Pennsylvania	Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
ES2607029T3 (es)	2007-11-28	2017-03-28	The Trustees Of The University Of Pennsylvania	Adenovirus que comprende una proteína hexónica de la cápside del adenovirus E de simio SAdV-39 y usos de la misma
ES2621165T3 (es)	2007-11-28	2017-07-03	The Trustees Of The University Of Pennsylvania	Adenovirus de simio de la subfamilia B SADV-28, -27, -29, -32, -33 y -35 y usos de los mismos
JP5661476B2 (ja)	2008-03-04	2015-01-28	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
EP2777185B1 (en)	2011-10-13	2016-08-24	Telefonaktiebolaget LM Ericsson (publ)	Method and node related to channel estimation

2008
- 2008-11-24 ES ES08857159.1T patent/ES2607029T3/es active Active
- 2008-11-24 WO PCT/US2008/013066 patent/WO2009073104A2/en not_active Ceased
- 2008-11-24 PT PT88571591T patent/PT2220241T/pt unknown
- 2008-11-24 HU HUE08857159A patent/HUE032142T2/en unknown
- 2008-11-24 KR KR1020157025105A patent/KR101662574B1/ko not_active Expired - Fee Related
- 2008-11-24 EP EP16188300.4A patent/EP3128010A1/en not_active Withdrawn
- 2008-11-24 EP EP08857159.1A patent/EP2220241B1/en not_active Not-in-force
- 2008-11-24 SG SG10201604001XA patent/SG10201604001XA/en unknown
- 2008-11-24 MX MX2010005858A patent/MX2010005858A/es active IP Right Grant
- 2008-11-24 HR HRP20161573TT patent/HRP20161573T1/hr unknown
- 2008-11-24 CN CN200880118591.5A patent/CN101883858B/zh not_active Expired - Fee Related
- 2008-11-24 US US12/744,441 patent/US8685387B2/en active Active
- 2008-11-24 LT LTEP08857159.1T patent/LT2220241T/lt unknown
- 2008-11-24 JP JP2010535987A patent/JP5740158B2/ja not_active Expired - Fee Related
- 2008-11-24 DK DK08857159.1T patent/DK2220241T3/en active
- 2008-11-24 CA CA2706258A patent/CA2706258C/en not_active Expired - Fee Related
- 2008-11-24 BR BRPI0819783-0A patent/BRPI0819783A2/pt not_active IP Right Cessation
- 2008-11-24 SI SI200831730T patent/SI2220241T1/sl unknown
- 2008-11-24 CA CA2964396A patent/CA2964396A1/en not_active Abandoned
- 2008-11-24 MX MX2014000110A patent/MX347246B/es unknown
- 2008-11-24 KR KR1020167026650A patent/KR101761691B1/ko not_active Expired - Fee Related
- 2008-11-24 AU AU2008331906A patent/AU2008331906B2/en not_active Ceased
- 2008-11-24 PL PL08857159T patent/PL2220241T3/pl unknown
- 2008-11-24 KR KR1020107014132A patent/KR101614364B1/ko not_active Expired - Fee Related
2014
- 2014-02-12 US US14/178,738 patent/US9359618B2/en active Active
- 2014-12-05 JP JP2014246768A patent/JP2015083006A/ja active Pending
2016
- 2016-05-13 US US15/154,368 patent/US20160244783A1/en not_active Abandoned
- 2016-05-18 JP JP2016099660A patent/JP6224769B2/ja not_active Expired - Fee Related
- 2016-12-13 CY CY20161101281T patent/CY1118351T1/el unknown

Also Published As

Publication number	Publication date
WO2009073104A2 (en)	2009-06-11
HUE032142T2 (en)	2017-08-28
JP2015083006A (ja)	2015-04-30
LT2220241T (lt)	2016-12-12
KR101761691B1 (ko)	2017-07-26
JP2016195595A (ja)	2016-11-24
KR101662574B1 (ko)	2016-10-05
US9359618B2 (en)	2016-06-07
CA2706258C (en)	2017-06-06
HRP20161573T1 (hr)	2017-02-10
CY1118351T1 (el)	2017-06-28
EP2220241B1 (en)	2016-09-14
AU2008331906B2 (en)	2014-03-06
ES2607029T3 (es)	2017-03-28
US20140155476A1 (en)	2014-06-05
SI2220241T1 (sl)	2017-02-28
US20100247490A1 (en)	2010-09-30
CA2706258A1 (en)	2009-06-11
JP5740158B2 (ja)	2015-06-24
PT2220241T (pt)	2016-12-26
CN101883858A (zh)	2010-11-10
AU2008331906A1 (en)	2009-06-11
KR101614364B1 (ko)	2016-04-22
WO2009073104A3 (en)	2009-08-20
EP3128010A1 (en)	2017-02-08
DK2220241T3 (en)	2017-01-09
WO2009073104A8 (en)	2016-03-31
MX2010005858A (es)	2010-06-11
KR20160118370A (ko)	2016-10-11
PL2220241T3 (pl)	2017-06-30
US20160244783A1 (en)	2016-08-25
CA2964396A1 (en)	2009-06-11
SG10201604001XA (en)	2016-07-28
KR20150108945A (ko)	2015-09-30
JP6224769B2 (ja)	2017-11-01
EP2220241A2 (en)	2010-08-25
MX347246B (es)	2017-04-19
KR20100109915A (ko)	2010-10-11
US8685387B2 (en)	2014-04-01
CN101883858B (zh)	2015-07-22
JP2011522513A (ja)	2011-08-04

Publication	Publication Date	Title
BRPI0819783A2 (pt)	2015-06-23	Subfamília simiana e adenovírus sadv-39, -25.2, -26, -30, -37 e -38 e usos dos mesmos.
EP1863558A4 (en)	2010-07-28	ELECTRO-SURGICAL CANNULA
NO2022027I1 (no)	2022-06-30	Combination of daunorubicin and cytarabine
FR20C1066I2 (fr)	2023-03-24	Pièges à gdf pour l'utilisation dans le traitment de l'anémie
DK1733707T3 (da)	2008-11-10	Infusionskanylesystem
FI20050450L (fi)	2006-10-30	Keskipakopumppu ja sen juoksupyörä
ATE526916T1 (de)	2011-10-15	Beleuchtete infusions- und inzisionskanüle
EP1976905A4 (en)	2012-08-01	MIXTURES OF BIOPOLYMERS WITH ACRYLIC POLYMERS
DK3176159T3 (da)	2021-01-18	4-phenyl-6-(2,2,2-trifluor-1-phenylethoxy)pyrimidin-baserede forbindelser og fremgangsmåder til anvendelse deraf
PT1849470T (pt)	2017-09-22	Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
EP2073738A4 (en)	2011-06-15	ABLATION CATHETER DEVICE WITH ONE OR MORE ELECTRODES
PT2963031T (pt)	2019-03-20	Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
BRPI0920976A2 (pt)	2015-08-18	Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular.
BRPI0817269A2 (pt)	2014-10-07	Análogos de azacitidina e usos dos mesmos
DE602007000091D1 (de)	2008-10-09	Radialventilator
EP2196936A4 (en)	2012-05-02	SAFE START-UP END UNIT, SAFE START-UP PROCEDURE, SAFE STARTER PROGRAM, RECORDING MEDIA AND INTEGRATED CIRCUIT
BRPI0816038A2 (pt)	2018-07-10	"composição de tratamento dos cabelos"
EP2054243A4 (en)	2011-04-13	DRYING PREVENTING SLIDER WRITING DEVICE
BRPI0907624A2 (pt)	2016-08-16	tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito
BRPI0715342A2 (pt)	2015-03-24	Derivados de 6-carboxi-normorfinano, síntese e usos dos mesmos
BRPI0907572A2 (pt)	2015-07-21	Derivados de fluorglicosídeos aromáticos, fármacos compreendendo os referidos compostos e uso dos mesmos
BRPI0923169A2 (pt)	2016-02-16	"composição de pasta sensível à pressão, e, dispositivo médico"
DE602004014713D1 (de)	2008-08-14	Optisches Multiplexverfahren und optischer Multiplexer, und optischer Verstärker, der diese verwendet
EP1971388A4 (en)	2012-06-20	TRANSPARENT CANNULA
DK2059161T3 (da)	2013-03-25	Maskine til vask af kirurgiske og/eller medicinske instrumenter

Legal Events

Date	Code	Title	Description
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
2019-05-28	B07E	Notice of approval relating to section 229 industrial property law	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-09	B07A	Technical examination (opinion): publication of technical examination (opinion)
2019-09-17	B08F	Application fees: dismissal - article 86 of industrial property law	Free format text: REFERENTE A 11A ANUIDADE.
2019-12-31	B08K	Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2541 DE 17-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.